---
title: 'Andexanet alfa in patients with factor Xa inhibitor associated intracranial
  hemorrhage: the prospective observational multicenter ASTRO-DE study'
date: '2025-01-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39834067/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250121170941&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: ASTRO-DE is the first prospective observational study systematically
  collecting standardized clinical routine data with andexanet alfa treatment. The
  study demonstrated favorable hemo-stasis and minimal mean hematoma volume growth
  in patients with ICH associated with apixa-ban or rivaroxaban ...'
disable_comments: true
---
CONCLUSIONS: ASTRO-DE is the first prospective observational study systematically collecting standardized clinical routine data with andexanet alfa treatment. The study demonstrated favorable hemo-stasis and minimal mean hematoma volume growth in patients with ICH associated with apixa-ban or rivaroxaban ...